Equities

BullFrog AI Holdings, Inc.

BFRG:NAQ

BullFrog AI Holdings, Inc.

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.02
  • Today's Change0.011 / 0.53%
  • Shares traded44.77k
  • 1 Year change-33.75%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 16:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence / machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.

  • Revenue in USD (TTM)0.00
  • Net income in USD-6.59m
  • Incorporated2020
  • Employees4.00
  • Location
    BullFrog AI Holdings, Inc.325 Ellington Blvd, Unit 317GAITHERSBURG 20878United StatesUSA
  • Phone+1 (240) 658-6710
  • Fax+1 (302) 531-3150
  • Websitehttps://www.bullfrogai.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Microbot Medical Inc0.00-11.21m15.74m22.00--4.07-----0.7963-0.79630.000.22870.00----0.00-158.98-53.28-199.48-62.65------------0.00------18.44---31.76--
Aprea Therapeutics Inc1.31m-13.51m15.89m7.00--0.7238--12.12-2.81-2.810.26464.280.0498----187,262.90-51.30-68.66-60.22-77.19-----1,030.42-42,112.84----0.00------87.32--90.61--
Synlogic Inc2.78m-37.18m16.43m6.00--1.25--5.92-4.09-4.090.2581.120.0638----462,833.30-85.46-40.57-105.90-43.82-----1,338.82-3,245.93----0.00--185.685.9913.40---48.05--
Tenax Therapeutics Inc0.00-14.56m16.53m5.00--0.17-----15.92-15.920.0028.520.00----0.00-26.08-199.16-26.84-285.64------------0.00------30.21------
Kazia Therapeutics Ltd (ADR)14.69k-13.32m17.11m12.00--0.1607--1,164.92-80.82-80.820.079734.410.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Bullfrog AI Holdings, Inc.0.00-6.59m17.51m4.00--4.13-----0.8556-0.85560.000.4870.00----0.00-149.16---173.23-------------370.560.043--550.00---91.11------
Cognition Therapeutics Inc0.00-34.27m17.65m25.00--1.24-----0.9553-0.95530.000.35490.00----0.00-103.30---150.91-------------260.860.00-------20.52------
NanoViricides Inc0.00-9.45m17.85m7.00--1.78-----0.7579-0.75790.000.71880.00----0.00-69.61-43.88-76.92-46.26------------0.00------3.43--16.23--
Neurosense Therapeutics Ltd0.00-7.51m17.91m16.00---------0.4392-0.43920.00-0.09430.00----0.00-154.72---470.03----------------------18.10------
OpGen Inc1.96m-22.39m18.22m100.00------9.27-20.01-20.011.66-8.650.1553--6.09---176.99-87.95-15,455.17-127.653.1515.42-1,139.66-794.78---20.25----31.113.0212.38--40.20--
Palatin Technologies, Inc.2.38m-32.35m18.35m30.00------7.70-1.98-1.980.1434-0.39320.3252----79,470.34-441.31-55.28---69.0895.90---1,357.06-1,359.14---------7.49-40.52-23.71--3.31--
Finch Therapeutics Group Inc0.00-14.17m18.39m18.00--1.29-----8.82-8.820.008.860.00-------25.20---28.80--------------0.00---87.57--34.80------
Mira Pharmaceuticals Inc0.00-11.24m18.62m3.00--5.73-----0.7287-0.72870.000.21970.00----0.00-169.22---191.76-------------3.320.00-------69.77------
MEI Pharma Inc0.00-46.60m18.72m28.00--0.7526-----6.99-6.990.003.730.00----0.00-72.25-21.09-79.28-23.99-------72.23----0.00--33.7667.75155.84---49.68--
Kairos Pharma Ltd0.00-2.74m19.26m----5.78-----0.2279-0.22790.000.25940.00-------92.10---264.70-------------2.610.0409-------72.57------
Data as of Nov 22 2024. Currency figures normalised to BullFrog AI Holdings, Inc.'s reporting currency: US Dollar USD

Institutional shareholders

3.11%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2024124.15k1.43%
Fortem Financial Group LLCas of 30 Sep 202451.40k0.59%
Geode Capital Management LLCas of 30 Sep 202435.95k0.41%
Virtu Americas LLCas of 30 Jun 202427.19k0.31%
Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Sep 202415.00k0.17%
XTX Markets LLCas of 30 Sep 202410.32k0.12%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 20246.48k0.07%
Tower Research Capital LLCas of 30 Sep 2024887.000.01%
Bank of America, NA (Private Banking)as of 30 Sep 202434.000.00%
Global Retirement Partners LLCas of 30 Sep 202415.000.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.